Resource Logo
Business Wire

Atreca, Inc. Receives $6 Million Investment to Apply Immune Repertoire CaptureTM Technology to Prevent and Treat Human Infectious Diseases




 

Investment and additional project funding from the Bill & Melinda Gates Foundation to accelerate vaccine development

SAN CARLOS, Calif.--(BUSINESS WIRE)--Atreca, Inc., announced today a collaboration with the Bill & Melinda Gates Foundation to accelerate the discovery and development of novel vaccines and therapeutics for human infectious diseases.

“We are grateful to the Bill & Melinda Gates Foundation for its vision,” said Tito A. Serafini, Ph.D., chief executive officer, chief scientific officer, and co-founder of Atreca, Inc. “This commitment from the foundation provides Atreca an opportunity to apply the Company’s Immune Repertoire CaptureTM technology to meet key challenges in global health.”

Immune Repertoire CaptureTM technology leverages next-generation sequencing to identify rapidly and comprehensively the set of functional antibodies produced in patients during an immune response. These antibodies both have utility themselves and can be employed to identify the targets of an immune response. Applied to human disease, Immune Repertoire CaptureTM is an engine for the discovery and development of antibody-based therapeutics, vaccines, diagnostics, and research reagents. Atreca recently licensed exclusive rights to the technology for all fields of use from Stanford University.

The foundation’s investment establishes a long-term collaboration between the parties. Under the terms of the agreement, Atreca will apply its Immune Repertoire CaptureTM technology in a particular set of infectious diseases and other conditions, and the Company will share with the foundation the results for use in the discovery and development of vaccines, therapeutics, and diagnostics to be deployed in a defined group of countries. In the first four years, the partnership will focus on at least three diseases identified: malaria, HIV/AIDS, and tuberculosis.

“Within a very short timeframe, we worked closely with the team at the foundation to bring together our two organizations in a creative manner,” said Paulette Dillon, chief business officer and co-founder of Atreca. “The structure of the agreement facilitates reaching the common goal of improving global health while at the same time allows each party to achieve its individual objectives.”

About Atreca, Inc.

Atreca, Inc., is a privately held biopharmaceutical company whose Immune Repertoire CaptureTM technology revolutionizes the discovery and development of a wide range of products.

The Company was founded in 2010 and has its headquarters in San Carlos, California.

For additional information, please visit: www.atreca.com.

About the Bill & Melinda Gates Foundation

Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people---especially those with the fewest resources---have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Jeff Raikes and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.

For further information please contact media@gatesfoundation.org.

Contacts

Company:
Atreca, Inc.
Paulette Dillon
Chief Business Officer
1-650-595-2661
info@atreca.com
or
Media:
Michele Parisi
1-925-429-1850
mparisi@biocommnetwork.com



 


Copyright © 2012 -Business Wire, Publisher. All rights reserved to Business Wire.Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. Business Wire.

Information in this article was accurate in September 25, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.